<DOC>
	<DOCNO>NCT02081079</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability ledipasvir/sofosbuvir ( LDV/SOF ) fixed-dose combination ( FDC ) participants chronic genotype 4 5 hepatitis C virus ( HCV ) infection measure proportion subject sustain virologic response ( SVR12 ) , define HCV RNA &lt; low limit quantification ( LLOQ ) 12 week discontinuation therapy .</brief_summary>
	<brief_title>Efficacy Safety Ledipasvir/Sofosbuvir Fixed-Dose Combination Treatment-Naive Treatment-Experienced Subjects With Chronic Genotype 4 5 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>HCV RNA â‰¥ 10^4 IU/mL screen Chronic genotype 4 5 HCV Infection Individuals may treatment naive treatment experience Presence absence cirrhosis , liver biopsy may require Healthy accord medical history physical examination exception HCV diagnosis Agree use two form highly effective contraception duration study History current evidence condition , therapy , laboratory abnormality circumstance might confound result study , interfere individual 's participation full duration study best interest individual opinion investigator Prior exposure approve experimental HCV specific direct act antiviral ( ) ( DAA ) NS3/4A protease inhibitor History clinically significant chronic liver disease Evidence history decompensated liver disease HIV chronic hepatitis B ( HBV ) infection Hepatocellular carcinoma ( HCC ) malignancy ( exception certain resolve skin cancer ) Chronic use immunosuppressive agent immunomodulatory agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HCV GT 4</keyword>
	<keyword>HCV GT 5</keyword>
</DOC>